Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company and a subsidiary of Fortress Biotech, Inc. The company is dedicated to developing and commercializing innovative cancer immunotherapy products that harness the patient's own immune system to target and eradicate cancer cells. Mustang Bio’s approach involves acquiring the rights to cutting-edge technologies through licensing or ownership, funding their research and development, and then either out-licensing or bringing these technologies to market.
Mustang Bio has established strategic partnerships with notable institutions, including the City of Hope National Medical Center (COH) and the Fred Hutchinson Cancer Research Center. These collaborations focus on developing advanced Chimeric Antigen Receptor (CAR) engineered T cell (CAR T) therapies for various cancers.
Among Mustang’s core projects, their key programs are in Phase 1 clinical trials at COH. The MB-101 program is aimed at treating brain cancer, while MB-102 is being developed as a therapeutic agent for acute myeloid leukemia. Additionally, Mustang Bio is concentrating on gene therapies for rare genetic disorders, CAR T therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Recently, Mustang Bio has reported positive interim data from their multicenter Phase 1/2 clinical trial, showcasing a favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients. For more detailed insights, visit the 65th ASH Annual Meeting and Exposition website.
For further information and ongoing updates about Mustang Bio, you can reach them through the following contacts:
- Jaclyn Jaffe and Nicole McCloskey - Mustang Bio, Inc., (781) 652-4500, ir@mustangbio.com
- Tony Plohoros - Media Relations Contact, 6 Degrees, (908) 591-2839, tplohoros@6degreespr.com
Mustang Bio, Inc. (Nasdaq: MBIO) reported its financial results and corporate highlights for the year ended December 31, 2022. The company focuses on cell and gene therapies, particularly its leading candidate MB-106 for treating B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. MB-106 has demonstrated a 96% overall response rate and a 75% complete response rate in trials. Financially, Mustang's cash position declined to $76.7 million from $110.6 million year-over-year. The net loss for 2022 was $77.5 million, or $0.75 per share. The company aims to disclose additional data from ongoing trials in 2023, supporting an accelerated approval strategy for key indications.
Mustang Bio, Inc. (Nasdaq: MBIO) announced that its CEO, Manuel Litchman, will participate in Cantor's The Future of Oncology Virtual Symposium. The panel discussion titled “CAR-Ts in Hematological Malignancies” is scheduled for April 3, 2023, at 12:00 p.m. ET. Mustang Bio focuses on cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company aims to enhance its R&D through strategic partnerships and licensing agreements. Mustang's innovative therapies are developed in collaboration with leading medical institutions, reinforcing its commitment to advancing healthcare solutions.
Mustang Bio, Inc. (Nasdaq: MBIO) announced that its President and CEO, Manuel Litchman, M.D., will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 3:00 p.m. EST. The conference will showcase over 30 SMiD cap healthcare companies and discuss advancements in immunotherapy, cell therapy, and oncology. Additionally, a replay of the session will be available post-event. Mustang is focused on developing cell and gene therapies for hematologic cancers and rare genetic diseases, aiming for potential cures through collaborations with leading medical institutions.
Mustang Bio (Nasdaq: MBIO) reported advancements in its CAR T cell therapy portfolio, highlighting the ongoing Phase 1/2 clinical trial of MB-106 for B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The company met enrollment targets and aims to provide safety and efficacy data in 2023. MB-106 shows high efficacy with a 100% overall response rate in Waldenstrom macroglobulinemia patients. Additionally, Mustang plans to file an IND for the combination therapy MB-109 for glioblastoma in 2023, and it anticipates further clinical advancements in its CAR T platform.
Mustang Bio (MBIO) announced its Q3 2022 financial results, highlighting significant advancements in its cell and gene therapy portfolio. The company treated its first patient in a Phase 1/2 trial for MB-106, targeting B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The ongoing trial at Fred Hutch continues to show promising results, with a 100% complete response rate in Waldenstrom macroglobulinemia patients. Financially, Mustang reported a net loss of $19 million for the quarter, with cash reserves decreasing to $92.4 million.
Mustang Bio announced promising interim results from the MB-106 Phase 1/2 clinical trial targeting Waldenstrom macroglobulinemia (WM) and other B-cell non-Hodgkin lymphomas (B-NHLs). The trial reported a 100% overall response rate (ORR) and a 75% complete response (CR) in various hematologic malignancies, with two WM patients achieving a complete response. The FDA granted Orphan Drug Designation for MB-106, enhancing its potential for expedited development. The data will be presented at the IWWM-11 workshop in Madrid, Spain, highlighting the therapy's efficacy and safety profile.
Mustang Bio, Inc. (Nasdaq: MBIO) has initiated a multicenter, open-label Phase 1/2 clinical trial for MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The trial marks a significant milestone, following promising interim results from 28 patients, showing a 96% overall response rate and a 75% complete response rate. The treatment demonstrated a favorable safety profile with no severe cases of cytokine release syndrome or neurotoxicity. Further efficacy data will be reported in Q4 2022.
Mustang Bio (NASDAQ: MBIO), a clinical-stage biopharmaceutical firm, has announced CEO Manuel Litchman will participate in two investor conferences in New York City. The H.C. Wainwright 24th Annual Global Investment Conference will occur on September 12, 2022, featuring a corporate update and one-on-one meetings. A presentation will be webcasted for 30 days. Additionally, Mustang will engage in a panel at the Cantor Cell & Gene Therapy Conference on September 15, 2022. Mustang specializes in cell and gene therapies targeting various cancers and rare diseases.
Mustang Bio, Inc. (NASDAQ: MBIO) announced its financial results for Q2 2022, reporting a cash balance of $108.4 million, down from $123.2 million in Q1 2022. The company highlighted significant milestones, including favorable interim Phase 1/2 data for its CAR T therapy MB-106 for B-cell cancers, achieving an overall response rate of 96%. Additionally, FDA granted Orphan Drug Designation to MB-106 for Waldenstrom macroglobulinemia. R&D expenses increased to $15.2 million, with a net loss of $19.1 million for the quarter. Mustang anticipates advancing its gene therapy programs in 2023.
Mustang Bio (NASDAQ: MBIO) announced the successful administration of LV-RAG1, an ex vivo lentiviral gene therapy, to the first patient in a Phase 1/2 trial for treating RAG1-SCID, a severe genetic immunodeficiency. This significant milestone reflects the potential of MB-110, licensed from LUMC, to offer new hope for SCID patients. The treatment resulted in a functioning immune system, marking a positive development in Mustang's clinical pipeline. The company anticipates further advancements and plans to initiate a pivotal Phase 2 trial for MB-107 in the latter half of the year.
FAQ
What is the current stock price of Mustang Bio (MBIO)?
What is the market cap of Mustang Bio (MBIO)?
What is Mustang Bio, Inc.?
What are Mustang Bio's core areas of focus?
Who are Mustang Bio's key partners?
What are Mustang Bio's lead programs?
What recent achievements has Mustang Bio reported?
How does Mustang Bio acquire its technologies?
What is CAR T therapy?
How can I contact Mustang Bio for more information?
Where can I find more detailed updates on Mustang Bio's clinical trials?
Who should media inquiries be directed to?
